VistaGen Therapeutics
VTGN
46 hedge funds and large institutions have $90M invested in VistaGen Therapeutics in 2023 Q4 according to their latest regulatory filings, with 24 funds opening new positions, 15 increasing their positions, 2 reducing their positions, and 12 closing their positions.
826% more call options, than puts
Call options by funds: $5.29M | Put options by funds: $571K
650% more repeat investments, than reductions
Existing positions increased: 15 | Existing positions reduced: 2
472% more capital invested
Capital invested by funds: $15.7M → $90M (+$74.2M)
100% more first-time investments, than exits
New positions opened: 24 | Existing positions closed: 12
35% more funds holding
Funds holding: 34 → 46 (+12)
33% more ownership
Funds ownership: 32.09% → 65.09% (+33%)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
TCM
TCG Crossover Management
Palo Alto,
California
|
+$10.1M |
| 2 |
BI
BVF Inc
San Francisco,
California
|
+$7.57M |
| 3 |
GPP
Great Point Partners
Greenwich,
Connecticut
|
+$7.03M |
| 4 |
NCM
Nantahala Capital Management
New Canaan,
Connecticut
|
+$6.88M |
| 5 |
Vanguard Group
Malvern,
Pennsylvania
|
+$5.98M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
IC
Ikarian Capital
Dallas,
Texas
|
-$1.2M |
| 2 |
SSA
Schonfeld Strategic Advisors
New York
|
-$726K |
| 3 |
Group One Trading
Chicago,
Illinois
|
-$285K |
| 4 |
MA
MYDA Advisors
Woodmere,
New York
|
-$262K |
| 5 |
BFM
Boothbay Fund Management
New York
|
-$246K |
VTGN Hedge Fund Activity: Q4 2023 in Review
46 of the 6,869 institutional investors tracked by Wall St. Rank reported a position in VistaGen Therapeutics (VTGN) for Q4 2023, worth a combined $90M — up 472% from $15.7M a quarter earlier.
Buyers outnumbered sellers: 24 funds opened new VTGN positions and 12 closed out — a net gain of 12 holders — while 15 added to existing stakes and 2 trimmed.
The largest buyer was TCG Crossover Management, opening a new position worth an estimated $10.1M. The largest seller was Ikarian Capital, exiting entirely with an estimated $1.2M sold.
- 46 institutional investors held VistaGen Therapeutics (VTGN) as of Q4 2023, up from 34 in Q3 2023.
- Funds reported $90M of VistaGen Therapeutics stock for Q4 2023, up 472% quarter-over-quarter.
- 24 funds opened new VistaGen Therapeutics positions in Q4 2023 and 12 closed out, a net change of +12 holders.
- The largest VistaGen Therapeutics buyer in Q4 2023 was TCG Crossover Management, an estimated $10.1M added.
- The largest VistaGen Therapeutics seller in Q4 2023 was Ikarian Capital, an estimated $1.2M sold.
Based on aggregated 13F filings for Q4 2023.